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Squamous cell carcinoma antigen recognized by T cells 3 (SART3), a tumor-associated
antigen expressed in many cancers, functions in tumor rejection. In this study, we investi-
gated its usefulness as an immunotherapeutic target in hepatocellular carcinoma (HCC).
Methods
The expression of SART3 in hepatoma cell lines and HCC tissues was investigated by
immunofluorescence and immunohistochemical analyses. Two peptides derived from
SART3 (SART3109 and SART3315) were used for immunological analysis. T-cell responses
were investigated by interferon-gamma (IFN-γ) enzyme-linked immunospot and cytotoxic T
lymphocyte (CTL) assays using peripheral blood mononuclear cells (PBMCs) in 47 patients,
and tumor-infiltrating lymphocytes in 8 of 47 patients with HCC. The safety of immunother-
apy using a SART3-derived peptide was investigated by vaccinations of SART3109 in 12
patients with HCC (trial registration: UMIN000005677).
Results
The immunofluorescence and immunohistochemical analyses showed that SART3 was
expressed in six HCC cell lines, and in HCC tissues including of alpha-fetoprotein-negative
individuals. SART3-specific CTLs were generated by stimulating PBMCs with the peptides,
and they showed cytotoxicity against HCC cells expressing the protein. Of the 47 HCC
patients, 25.5% and 10.6% showed significant responses to SART3109 and SART3315,
respectively. The infiltration of SART3109-specific IFN-γ-producing CTLs into the tumor site
was confirmed. In the vaccination study, no severe adverse events were observed, and the
peptide-specific CTLs were newly induced in four of five patients tested.
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Conclusions





Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death [1]
and its recurrence rate is very high [2]. To protect against recurrence, tumor antigen-specific
immunotherapy is an attractive option. During the last two decades, various tumor antigens
associated with HCC have been identified as potential candidates for peptide vaccines [3–5].
We have also identified several HCC-specific epitopes, and have used some of them for human
trials of HCC immunotherapy [6–9].
Squamous cell carcinoma antigen recognized by T cells 3 (SART3) is a tumor-associated
antigen (TAA), and is also known as the human homolog of precursor RNA processing, gene
24 (Prp24) [10]. It is expressed in many malignant tumor cell lines and functions in tumor
rejection [11, 12]. In addition, peptides containing SART3 epitopes are capable of generating
cytotoxic T lymphocytes (CTLs) and thus have been reported to be effective in immunother-
apy to treat several kinds of cancer [13–15]. These reports suggest that SART3 might be useful
as a target antigen for HCC immunotherapy.
In this study, we examined SART3 expression in various hepatoma cell lines and HCC tis-
sues of patients, and analyzed immune responses to SART3 using peripheral blood mononu-
clear cells (PBMCs) and tumor-infiltrating lymphocytes (TILs). Furthermore, to confirm the
usefulness of HCC immunotherapy targeting SART3, we analyzed the safety and cellular
immune responses induced in patients vaccinated with SART3-derived peptide.
Patients and Methods
Patients
Fifty-seven human leukocyte antigen (HLA)-A24-positive HCC patients were examined for
cellular immune responses against SART3-derived peptides. In the vaccination study, twelve
HLA-A24-positive HCC patients who were treated in Kanazawa University Hospital by radio-
frequency ablation (RFA) and achieved complete necrosis of the tumor with a safety margin
between June 1, 2011 to March 31, 2013 were enrolled (Fig 1 and S1 and S2 Files). The follow-
up period in the vaccination study was March 31, 2015. The diagnosis of HCC was histologi-
cally confirmed via ultrasound (US)-guided needle biopsy specimens in 18 cases, surgical
resection in 11 cases, and autopsy in 4 cases. For the remaining 14 patients, the diagnosis was
based on angiography and/or dynamic computed tomography (CT) [16]. The pathological
grading of tumor cell differentiation was assessed according to the general rules for the clinical
and pathological study of primary liver cancer [17]. The severity of liver disease was evaluated
according to the criteria of Desmet et al. using biopsy specimens of liver tissue [18]. In total, 19
healthy normal donors, 22 chronic hepatitis C patients (including 10 cirrhotic patients) with
HLA-A24, who were diagnosed by liver biopsy, and 12 patients with surgical resection of
HCC, served as controls. Written informed consent was obtained from each patient. The study
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protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, reflected in a
priori approval by the regional ethics committee (Medical Ethics Committee of Kanazawa Uni-
versity, No. 1017).
Cell lines
Six human hepatoma cell lines (HLF, Hep3B, Alex, HepG2, HLE, and Huh7), PaCa-2 (pancre-
atic cancer cell line), and the HLA-A2402 gene-transfected C1R cell line (C1R-A24) was cul-
tured as described in detail previously [9].
Immunofluorescence and immunohistochemical analyses
The expression of SART3 was examined by Immunofluorescence and immunohistochemical
analyses described in detail previously [9] with the following modifications. For immunofluo-
rescence analyses, the six different hepatoma cell lines listed above and PaCa-2 (as a positive
control) were fixed in acetone with methanol for 5 min and incubated with rabbit anti-human
SART3 (Aviva Systems Biology, San Diego, CA, USA; 1:125) or mouse anti-human alpha-feto-
protein (AFP) (Nichirei Bioscience, Tokyo, Japan) antibody overnight at 4˚C. Alexa Fluor1
488-conjugated anti-rabbit (Invitrogen, Eugene, OR, USA; 1:500) and anti-mouse immuno-
globulin G (IgG) (Invitrogen, Tokyo, Japan) were used for SART3 and AFP detection,
Fig 1. Flow chart of the vaccination study.
doi:10.1371/journal.pone.0170291.g001
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respectively. Expression of SART3 and AFP in HCC tissue was examined using both cancerous
and non-cancerous tissue obtained from 26 patients. The tissues sections were deparaffinized,
treated in a pressure cooker for 1–4 min, and incubated with rabbit anti-human SART3 or
AFP (Dako Cytomation, Inc., Carpinteria, CA, USA) antibody overnight at 4˚C. The tissue
sections were visualized using the Dako EnVision™+ System (Dako Cytomation). A semi-
quantitative, four-category classification system (negative: no staining, low:< 20% of the area
stained, moderate: 20–80% of the area stained, high: > 80% of the area stained) was used to
compare expression levels, as described in our previous report [9].
Enzyme-linked immunospot (ELISpot) assay
The PBMCs and TILs were isolated as described previously [8]. ELISpot assays were per-
formed as reported previously with the following modifications [8, 9]. Two different peptides
derived from SART3—SART3109 (VYDYNCHVDL) and SART3315 (AYIDFEMKI)—were
used for the detection of CTLs. They correspond to the HLA-A24-restricted CTL epitope [11,
12]. A human immunodeficiency virus (HIV) envelope-derived peptide (HIVenv584) was used
as a negative control [19]. 10 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma) or a cyto-
megalovirus (CMV) pp65-derived peptide (CMVpp65328) was used as a positive control [20].
The peptides were synthesized at Sumitomo Pharmaceuticals (Osaka, Japan) and Genemed
Synthesis, Inc. (San Antonio, TX, USA). Responses to peptides were considered positive if the
number of specific spots was more than 10, and if the number of spots in the presence of an
antigen was at least twofold greater than the number in its absence.
CTL induction and cytotoxicity assay
SART3109 (VYDYNCHVDL) was used to produce SART3-specific T cells. CTLs were
expanded from PBMCs as detailed previously [8, 9]. C1R-A24 cells and human hepatoma cell
lines were used as targets. Cytotoxicity was evaluated using a chromium-release assay. The per-
cent cytotoxicity was calculated as previously described [8]. For the assay using the hepatoma
cell lines, cytotoxicity was considered positive when it was higher than that of CTLs against
K562, showing non-specific lysis.
Vaccination study
To investigate the safety and immunological effects of SART3-derived peptide in HCC
patients, twelve HLA-A24-positive HCC patients were enrolled in the present vaccination
study. The self-selection method was used in patient recruitment. They were vaccinated with
SART3109 into the subcutaneous tissue of the armpit from 4 weeks after RFA and were
observed for 3months after vaccination. The peptide utilized in the present study was prepared
under conditions of Good Manufacturing Practice (NeoMPS, Inc., San Diego, CA, USA). The
method of manufacturing a peptide vaccine and vaccination to the patients were similar to our
previous report [9]. In detail, 0.04–4 mg/mL peptide solution and incomplete Freund’s adju-
vant (Montanide ISA-51; Seppic SA, Paris, France) were mixed and emulsified as a peptide
vaccine, and a total of 1.5 mL of the vaccine was injected to the patients received three vaccina-
tions biweekly. Every two weeks, toxicity of the vaccine was assessed using the National Cancer
Institute’s Common Terminology Criteria for Adverse Events (ver. 3.0). Of These patients,
three patients each were treated with 1/100 (0.03 mg) or 1/10 (0.3 mg) dose of the peptide.
After confirming the safety of the peptide, the remaining six patients received 3 mg of the pep-
tide. The study was designed as a dose escalation study and its trial registration number was
UMIN000005677.
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To investigate the immunological effect, the ELISpot assay using PBMCs obtained before
vaccination and at 4 weeks after the final vaccination was performed. Responses to vaccination
were considered positive if more than 10 specific spots were detected and if the number of
spots after vaccination was at least twofold that before vaccination. After final vaccination,
HCC recurrence was evaluated by dynamic CT or magnetic resonance imaging (MRI) every 3
months.
Statistical analysis
Data are expressed as means ± standard deviation. The Mann-Whitney U test was used for sta-
tistical analyses of SART3 expression in HCC and non-cancerous liver tissues. The χ2 test with
Yates’ correction and the unpaired t-test were used for univariate analysis of the effects of vari-




The clinical profiles of the 19 healthy normal donors, 12 patients with chronic hepatitis C, 10
patients with liver cirrhosis, and 47 patients with HCC analyzed in the present study are
shown in Table 1. Using the TNM Classification of Malignant Tumours 7th edition, of the
Union for International Cancer Control, 11, 21, 3, 3, 1, 1, and 7 patients were classified as hav-
ing stage I, II, IIIA, IIIB, IIIC, IVA, and IVB tumors, respectively.
Expression of SART3 in hepatoma cell lines and HCC tissues
SART3 was expressed in all of the hepatoma cell lines examined. Its distribution was cyto-
plasmic and nuclear, similar to that for PaCa-2, as reported elsewhere (Fig 2A) [11]. The
Table 1. Characteristics of the patients studied.
Normal donors a Chronic hepatitis a Liver cirrhosis a HCC
No. of patients 19 12 10 47
Age (years) b 35±8 54±11 59±11 66±8
Sex (M/F) 14/5 7/5 4/6 37/10
ALT (IU/L) b ND 104±119 89±74 65±32
AFP (ng/ml) b ND 12±4 87±147 1589±7540
Diff. degree of HCC (well/moderate/poor/ND) c ND ND ND 13/17/3/14
Tumor size (large/small) d ND ND ND 38/9
Tumor multiplicity (multiple/solitary) ND ND ND 30/17
Vascular invasion (+/-) ND ND ND 16/31
TNM stage (I/II/IIIA/IIIB/IIIC/IVA/IVB) ND ND ND 11/21/3/3/1/1/7
Liver function (Child-Pugh A/B/C) ND 12/0/0 6/4/0 30/14/3
Etiology (HBV/HCV/Others) e ND 0/11/1 1/6/3 8/35/4
a ND: not determined.
b Data are expressed as the mean ± SD.
c Histological degree of HCC; well: well-differentiated, moderate: moderately differentiated, poor: poorly differentiated, ND: not determined.
d Tumor size was divided into either ‘small’ (≦2 cm) or ‘large’ (>2 cm).
e HBV: hepatitis B virus; HCV: hepatitis C virus.
doi:10.1371/journal.pone.0170291.t001
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expression of SART3 was observed even in the hepatoma cell lines not expressing AFP (HLF,
HLE).
The expression of SART3 in HCC tissues was examined using samples obtained from 26
HCC patients by US-guided needle tumor biopsy or surgical resection and compared with the
expression in non-cancerous tissues. A representative result for one HCC patient is shown in
Fig 2B. In this case, SART3 expression was observed in HCC tissue but not in non-cancerous
areas, and AFP was not detected in HCC tissue. However, in some cases, the expression of
SART3 was observed in non-cancerous tissues.
Fig 2. Expression of squamous cell carcinoma antigen recognized by T cells 3 (SART3) in hepatocellular carcinoma (HCC) cell
lines and human HCC tissues. (A) Immunofluorescence analysis of the expression of SART3 in hepatoma cell lines. Original
magnification, ×400. (B) Immunohistochemical analysis of the expression of SART3 and alpha-fetoprotein (AFP) in sequential non-
cancerous and HCC tissue sections. Original magnification, ×200 (left) and ×400 (right). (C) Analysis of SART3 expression levels among the
four groups (HCC: tumor tissue in HCC patients, Non-tumor: non-tumor tissue in HCC patients, Disease control: liver tissue in disease
control group, Normal liver: tissue from HCC with normal liver patients). Closed and open circles show the level of SART3 expression in the
patients with liver cirrhosis and chronic hepatitis, respectively. Grayish circles show the level of SART3 expression in the patients with
normal liver. (D) The expression of SART3 was also compared with AFP expression in HCC tissues.
doi:10.1371/journal.pone.0170291.g002
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Therefore, to compare the levels of these proteins between cancerous and non-cancerous
tissues, the expression was semi-quantitatively classified into four categories (negative, low,
moderate, and high) as described in the Patients and Methods section, and analyzed in 26
patients. The expression of SART3 in non-cancerous tissue was observed in 18 (69%) of 26
patients, and the expression levels of SART3 were higher in HCC tissue than in non-cancerous
tissue (P = 0.002) (Fig 2C). The expression levels in liver tissue were also observed in disease
control group (the patients with chronic hepatitis liver cirrhosis) and normal liver group (the
patients with surgical resection of HCC) as controls; however, these expression levels both in
disease control group and normal liver group were lower than those in HCC tissue (P = 0.033
and<0.001, respectively). The expression of SART3 and AFP in HCC tissue was observed in
26 (100%) and 12 (46%) of 26 patients, respectively (Fig 2D). The expression of SART3 in the
absence of AFP expression was observed in 14 patients.
Detection of SART3-specific T cells assessed by interferon (IFN)-γ
ELISpot analysis
ELISpot assays were performed using PBMCs from the HCC patients to investigate the fre-
quency of CTLs specific for the peptides derived from SART3 (Fig 3). Of the 47 HCC patients,
25.5% (12 patients) and 10.6% (5 patients) showed significant responses to SART3109 and
SART3315, respectively (Fig 3A). The same analyses were performed in the healthy donors and
disease control group (patients with chronic hepatitis and cirrhosis without HCC). Among the
19 healthy donors, 10.5% (2 donors) and 21.1% (4 donors) showed significant responses to
SART3109 and SART3315, respectively. Among the 22 patients of the disease control group,
0.0% and 9.1% (2 patients) showed significant responses to SART3109 and SART3315, respec-
tively (Fig 3B). Significant differences in the frequency of SART3109-specific spots were
detected between patients with HCC, disease-control patients, and healthy donors (Fig 3C).
On the other hand, no significant differences were detected in those of the SART3315 among
the three groups. These results suggested that SART3109 peptide was preferable as a peptide
vaccine. Significant responses specific to CMVpp65328 were detected in 46.8%, 42.1%, and
36.4% of HCC patients, healthy donors, and the disease control group, respectively, with no
significant difference among these three groups. No patients showed a significant response
specific to HIVenv584.
To clarify the clinical characteristics of SART3-specific T-cell responses in HCC patients,
the clinical background was compared between patients who showed positive responses to
SART3-derived peptides in the ELISpot assay and those who did not. The clinical features of
both groups were not significantly different in terms of age, gender, serum AFP levels, differ-
entiation of HCC, tumor multiplicity, vascular invasion, TNM factors and stages, histology of
the non-tumor liver, liver function, or the type of viral infection (S1 Table). SART3-specific T
cells could be generated even in the early stages of HCC and independent of a hepatitis viral
infection.
Detection of SART3-specific T cells in TILs
Next, to examine the existence of SART3-specific T cells in TILs, we performed a similar analy-
sis in another eight patients from whom samples of both PBMCs and TILs could be obtained.
In the assay using PBMCs and TILs, one (12.5%) and four (50.0%) of the eight patients, respec-
tively, showed significant responses to SART3109 (Fig 4). SART3-specific T cells in TILs were
observed even in patients without SART3-specific T-cell responses in PBMCs.
SART3-Specific T Cell Responses in HCC
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Fig 3. Immune responses of SART3-specific T cells in HCC patients. (A) Interferon (IFN)-γ enzyme-
linked immunospot (ELISpot) assay was performed using SART3, HIVenv584, and cytomegalovirus pp65328-
derived peptides with peripheral blood mononuclear cells (PBMCs) of HCC patients. % indicates the
proportion of patients who showed positive responses. (B) IFN-γ ELISpot assay in healthy donors and
disease control groups. “N” denotes normal donors. “C” denotes the patients with chronic hepatitis. “L”
denotes the patients with liver cirrhosis. % shows the proportion of patients who exhibited positive responses.
(C) Comparison of the mean number of SART3-derived peptide-specific spots among the three groups. Error
SART3-Specific T Cell Responses in HCC
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Comparison of SART3-specific T-cell responses with AFP-specific T-cell
responses
To compare SART3-specific and AFP-specific T-cell responses, an IFN-γ ELISpot assay using
an AFP-derived peptide (AFP403) [6] was also performed in the same HCC patients(S1 Fig). A
significant response was detected in 10.6% (S1A Fig) of these patients. In a comparison
between the mean numbers of specific spots for SART3109 and for AFP403, the frequency of
SART3109-specific T cells was not higher than that of AFP403 in all patients (S1B Fig). However,
in the patients who showed significant responses for either SART3109 or AFP403, the frequency
of SART3109-specific T cells was significantly higher than that of AFP403 (S1C Fig).
Cytotoxic activity of SART3-specific T cells against hepatoma cell lines
We investigated whether SART3109 is capable of generating peptide-specific CTLs from
PBMCs. Because of the limitation of blood samples, CTL assay using PBMCs from 47 HCC
patients could not be performed. Thus, PBMCs derived from other 18 HCC patients were used
to assess the cytotoxicity (Fig 5 and S2 Table). The induction of SART3-specific T cells by pep-
tide stimulation was observed in 2 of 18 patients (Fig 5A). These CTLs also exhibited cytotoxic-
ity against hepatoma cell lines with the HLA-A24 molecule and expression of SART3, which
bars indicate the standard deviations. Black and white bars indicate the frequencies of SART3109- and
SART3315-specific T cells, respectively.
doi:10.1371/journal.pone.0170291.g003
Fig 4. IFN-γ ELISpot assay using tumor-infiltrating lymphocytes (TILs) against one of the SART3-
derived peptides (SART3109) in HCC patients. ELISpot was performed in eight patients from whom
samples of both PBMCs and TILs could be obtained. Open and solid bars show the frequency of
SART3-specific T cells in PBMCs and TILs, respectively.
doi:10.1371/journal.pone.0170291.g004
SART3-Specific T Cell Responses in HCC
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correspond to HLE and HLF, but not against Hep3B and Huh7 cells without HLA-A24
(Fig 5B).
Clinical safety of SART3109 peptide and its immunological effects
The clinical profiles of the 12 HCC patients with vaccination are shown in Table 2. The
patients in group A, B and C were vaccinated with 0.03, 0.3 and 3 mg of the peptide, respec-
tively. The treatment was well-tolerated and there were no serious adverse events. The most
common adverse event was grade 1 injection-site reaction manifesting as pain, pruritus, and
skin induration. Worsening of hepatitis or liver function was not observed in any of the vacci-
nated patients. Positive T-cell responses after vaccination were observed in 8 of 12 (66.7%)
patients: two of three (66.7%) patients in group A, three of three (100.0%) in group B, and
Fig 5. Induction of SART3-specific T cells in HCC patients. (A) Representative results of the cytotoxic T lymphocyte (CTL) assay. The
results are shown as specific cytotoxic activity, which was calculated as follows: (cytotoxic activity in the presence of peptide)–(cytotoxic
activity in the absence of peptide); findings were considered positive at > 10%. (B) CTL assays [effector-to-target (E/T) ratio of 50:1] were
performed in 18 HCC patients. The results are also shown as specific cytotoxic activity. Solid bars show the results for one patient. (C)
Cytotoxicity of SART3-specific T-cell lines derived from the peptide was also measured against hepatoma cell lines. The cytotoxicity was
considered positive when it was higher than that against K562, which shows non-specific lysis (E/T ratio of 50:1). Representative results are
shown.
doi:10.1371/journal.pone.0170291.g005
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SART3-Specific T Cell Responses in HCC
PLOS ONE | DOI:10.1371/journal.pone.0170291 January 23, 2017 11 / 16
three of six (50.0%) patients in group C. In four of five (80.0%) patients without positive T-cell
responses before vaccination, the SART3-derived peptide-specific CTLs were newly induced
(Fig 6). The median relapse-free survival of group A, B, and C were 280, 329 and 536 days,
respectively (S2 Fig). Although there was no statistical significance on account of the small
number of patients, the recurrence rate in the patients with the CTL responses after vaccina-
tion (3 of 8 patients, 37.5%) was lower than that in the patients without CTL responses (2 of 4
patients, 50%) at 300 days after RFA (Table 2).
Discussion
Several TAAs and their CTL epitopes expressed in HCC have been discovered over the past
10–15 years [6–9, 21–24] and several trials of TAA-derived peptides for the treatment of HCC
(e.g., AFP, human telomerase reverse transcriptase, and glypican-3) have been performed [25–
27]. In these studies, the anti-tumor effects were very limited. Therefore, there is still a need to
identify other TAAs as therapeutic targets for HCC immunotherapy.
The important factors to consider when determining the usefulness of TAAs for peptide
vaccine therapy are the immunogenicity, specificity, oncogenicity, expression levels, percent-
age of positive cells, and number of patients with antigen-positive cancer [28]. In the present
study, the expression of SART3 was confirmed in 6/6 (100%) hepatoma cell lines. Further-
more, the expression of SART3 was detected in the HCC tissue of all patients, and was inde-
pendent of the expression of AFP in the tumor. These results suggest the advantage of this
antigen as a target of immunotherapy for HCC. However, the expression of SART3 was also
observed in non-cancerous tissues of HCC patients and liver tissue in the patients with chronic
hepatitis or liver cirrhosis without HCC, although less frequently and at lower levels than in
HCC tissue. Our results are consistent with the recent findings that SART3 is actually the
Fig 6. Interferon(IFN)-γ enzyme-linked immunospot assays of PBMCs to SART3-derived peptide (SART3109) or control peptides
(CMVpp65328) in HCC patients with RFA and SART3109 peptide vaccination. White and black bars show the T-cell responses before
and after vaccination, respectively. An asterisk denotes more than 50 specific spots.
doi:10.1371/journal.pone.0170291.g006
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human homologue of Prp24p, and is expressed in some normal tissues including liver tissue
[10]. Such results imply that immunotherapy targeting SART3 may have adverse effects on
liver tissue expressing the protein. However, previous studies using SART3-derived peptides
as a vaccine for several cancers have found them to be safe, suggesting that immunotherapy is
applicable to HCC [15, 29]. The results of the clinical trial that we performed as part of the
present study also showed the safety of SART3-derived peptides, even in the patients with
chronic hepatitis or cirrhosis.
With regard to the immunogenicity of SART3, we showed that SART3-specific CTLs could
be generated by stimulating PBMCs with peptides, and the CTLs were cytotoxic to hepatoma
cell lines. In the ELISpot assay, SART3-specific immune responses were observed frequently
only in HCC patients, and the frequency of CTLs was higher in the HCC patients than in the
control groups. CTLs were also detected among TILs, suggesting that they infiltrate into the
tumor. In a vaccination study with a SART3-derived peptide, seven patients had a SART3-der-
ived peptide-specific T-cell response before vaccination, and newly induced SART3-specific
CTLs were observed in four of five (80.0%) patients; this is similar to the frequency of respon-
sive patients reported in other peptide vaccination studies [26, 27], suggesting that SART3109 is
an immunogenic peptide. On the other hand, SART3-specific immune responses were lower
in patients C3 and C5 and had disappeared in patients A3, C4, and C6, suggesting possible
changes in circulating CTL precursors. The CTLs activated by vaccination might have infil-
trated the tumor tissues and induced an immune response to the tumor cells. Thus, it became
difficult to detect CTLs in the PBMCs of the patients. Our ELISpot data using PBMCs and
TILs (Fig 4) might support this speculation.
Apart from the induction of CTLs, the efficacy of SART3-derived peptides for a vaccine for
advanced HCC is still unclear. Other recent studies using SART3-derived peptides for other
advanced cancers showed the induction of cellular immune responses and clinical responses
for certain patients [15, 29]. Upon analyzing the prognosis of patients with RFA and SART3-
derived peptide vaccination in the present study, the recurrence rate in the patients with an
increase in the peptide-specific CTLs after vaccination was lower than that in the patients with-
out an immune response. Although further studies are necessary to evaluate the efficacy of
SART3-derived peptides for HCC, taken together with the results of previous studies, our
results suggest that SART3 can be considered an optimal antigen that satisfies most of the cri-
teria [28].
In conclusion, SART3 is a potential candidate for a TAA with immunogenicity, and pep-
tides derived from this protein may be applied to HCC immunotherapy.
Supporting Information
S1 Fig. Comparison of the frequency of squamous cell carcinoma antigen recognized by T
cells 3 (SART3) and alpha-fetoprotein (AFP)-specific T cells. (A) Interferon-γ enzyme-
linked immunospot assays were performed using peripheral blood mononuclear cells of hepa-
tocellular carcinoma patients against AFP-derived peptides. (B) Comparison of the frequency
of AFP403 and SART3109-specific T cells in all patients. (C) Comparison of the frequency of
AFP403 and SART3109-specific T cells in patients who showed a positive T-cell response.
(TIF)
S2 Fig. Relapse-free intervals of the vaccinated patients. The median relapse-free intervals
were 280, 329, and 536 days in groups A, B, and C, respectively, although the peptide-specific
responses in group C tended to be lower.
(TIF)
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S1 File. Protocol for a clinical trial in English.
(DOC)
S2 File. Protocol for a clinical trial in original language (in Japanese).
(DOC)
S1 Table. Univariate analysis of the effects of variables on the T cell response against
SART3.
(TIF)
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